Souhaitez-vous accéder aux communiqués récents ?

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

Silver Spring, MD, May 20, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration announced today that it issued warning letters to eight retailers for selling unauthorized tobacco products,...

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived...

AI Products Showcase

Washington, DC, May 14, 2026 (GLOBE NEWSWIRE) -- The Personalized Medicine Coalition released a new report documenting the U.S. Food and Drug Administration’s continued progress in advancing...

Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease

White Oak, Md., May 11, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is soliciting input on efforts with respect to drug repurposing to help address unmet...

MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the...